Fisetin-dose 1
Phase 2
Fisetin-dose 1 is one of 36 therapeutic programs targeting Sepsis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
100 competitors in Sepsis
#DrugCompanyPhaseTrials
1Antibiotics
MMelinta Therapeutics, Inc.
Phase 3
N-Acetylcysteine (NAC) Treatment
TThe First Affiliated Hospital of Soochow University
Phase 3
Decadron
AAspen Global Incorporated
Phase 2
G-CSF
AArog Pharmaceuticals, Inc.
Phase 2
Nafamostat Mesylate
EEnsysce Biosciences
Phase 3
Hydrocortisone Administration
UUniversity of Virginia
Phase 3
AZD4144
AstraZenecaPhase 2
Simdax
Orion Corporation, Orion PharmaPreclinical
Zyvox
PfizerPreclinical
Zemplar
AbbViePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Fisetin-dose 1. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Minnesota